Overall, consistent findings across multiple studies underscore the potential of EZH2 as a therapeutic target and prognostic biomarker in HCC while emphasizing the need for further research to clarify its mechanistic pathways and interactions within the tumor microenvironment. Here, EZH2 is linked to hepatocellular carcinoma.